A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting

Exclusion Criteria

• •Combined valvular surgery.
• •A second surgery.
• •Emergency surgery (a selective operation which change to emergency surgery in some special medical condition).
• •Serum creatinine\>130μmol/L.
• •Oral clopidogrel therapy stops less than 5 days before the surgery.
• •Oral anti-coagulation therapy (warfarin) that cannot be withheld.
• •History of gastrointestinal or vaginal bleeding, Active pathological bleeding (e.g. active gastroduodenal ulcer or cerebral haemorrhage), history of postoperative gastrointestinal bleeding.
• •Uric acid nephropathy, history of postoperative gastrointestinal bleeding.
• •History of cerebral haemorrhage.
• •Any other condition that may influence platelet count and function.
• •Postoperative chest drainage \> 200 ml/hr for two hours and more, re-operation for bleeding with persistent cardiac tamponade.
• •Treated with IABP or ECMO after operation.
• •Any other condition that may put the patient at risk (e.g., recurrent ventricular arrhythmias, peri-operative myocardial infarction, cancer).
• •Contraindication to aspirin, clopidogrel and ticagrelor or other reason that study drug should not be administered (e.g., hypersensitivity, moderate or severe liver disease).
• •Previous enrollment in other investigational drug or device study within 30 days.
• •Being or planning to pregnant.